Approved Use1

Beleodaq® (belinostat) is a prescription medicine used to treat people with a type of cancer called peripheral T-cell lymphoma (PTCL) that comes back or does not respond to previous treatment.

This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established.

Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.

It is not known if Beleodaq® is safe and effective in children.